Pulse Biosciences (PLSE)
(Real Time Quote from BATS)
$13.73 USD
-0.31 (-2.21%)
Updated Aug 7, 2024 01:46 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PLSE 13.73 -0.31(-2.21%)
Will PLSE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PLSE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLSE
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
PLSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PLSE
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
Healthcare 2024 Second Half Outlook
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX? nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering